Elmind Capital LP
Elmind Capital LP is an SEC-registered investment adviser that reports managing 1 hedge fund on Form ADV. It reports $613.6 million in regulatory assets under management. Its private funds, of all types, hold $613.6 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +18.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +18.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $613.6 millionForm ADV Item 5.F
- Gross assets of private funds
- $613.6 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 2Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 333910
- Latest Form ADV
- 09/03/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +11.3% | +14.8% |
| Q1 2026 | +6.1% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 30 share positions ($403,836,290) reported by Elmind Capital, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Celldex Therapeutics Inc New8.91%
- Legend Biotech Corp7.73%
- Syndax Pharmaceuticals Inc7.47%
- Cogent Biosciences Inc6.87%
- Relay Therapeutics Inc6.55%
- Amylyx Pharmaceuticals Inc6.45%
- Viridian Therapeutics Inc6.25%
- Vaxcyte Inc5.25%
- Urogen Pharma LTD4.94%
- Travere Therapeutics Inc4.70%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Celldex Therapeutics Inc New | $35,975,100 | 8.91% | 1,110,000 | +12.12% |
| Legend Biotech Corp | $31,220,856 | 7.73% | 1,569,676 | +175.11% |
| Syndax Pharmaceuticals Inc | $30,174,000 | 7.47% | 1,605,000 | -13.48% |
| Cogent Biosciences Inc | $27,753,079 | 6.87% | 866,742 | -25.97% |
| Relay Therapeutics Inc | $26,448,286 | 6.55% | 1,465,279 | Unchanged |
| Amylyx Pharmaceuticals Inc | $26,037,516 | 6.45% | 894,760 | +698.89% |
| Viridian Therapeutics Inc | $25,221,329 | 6.25% | 1,224,931 | +24.37% |
| Vaxcyte Inc | $21,186,146 | 5.25% | 372,340 | -17.69% |
| Urogen Pharma LTD | $19,953,393 | 4.94% | 491,100 | +309.25% |
| Travere Therapeutics Inc | $18,994,688 | 4.70% | 322,600 | +10.25% |
| Cullinan Therapeutics Inc | $14,778,857 | 3.66% | 962,792 | +39.54% |
| Pharvaris N V | $14,456,390 | 3.58% | 455,750 | -13.31% |
| Vera Therapeutics Inc | $14,095,166 | 3.49% | 436,518 | Unchanged |
| Cytomx Therapeutics Inc. | $12,376,000 | 3.06% | 4,550,000 | Unchanged |
| Beam Therapeutics Inc | $11,646,464 | 2.88% | 476,338 | Unchanged |
| Nurix Therapeutics Inc | $10,906,600 | 2.70% | 460,000 | Unchanged |
| Summit Therapeutics Inc | $8,350,496 | 2.07% | 493,820 | Unchanged |
| United Therapeutics Corp Del | $8,128,350 | 2.01% | 15,000 | Unchanged |
| Immunocore Hldgs PLC | $7,758,571 | 1.92% | 256,143 | +215.67% |
| Krystal Biotech Inc | $7,316,320 | 1.81% | 22,000 | Unchanged |
| Alumis Inc | $5,539,248 | 1.37% | 749,560 | +15.32% |
| Biocryst Pharmaceuticals Inc | $4,331,600 | 1.07% | 520,000 | Unchanged |
| Sutro Biopharma Inc | $3,677,349 | 0.91% | 228,265 | +612.50% |
| MBX Biosciences Inc | $3,575,820 | 0.89% | 61,000 | -32.97% |
| DBV Technologies S A | $3,116,400 | 0.77% | 265,000 | Unchanged |
| Supernus Pharmaceuticals | $3,012,800 | 0.75% | 70,000 | Unchanged |
| Biomarin Pharmaceutical Inc | $2,820,000 | 0.70% | 47,000 | Unchanged |
| Septerna Inc | $1,934,744 | 0.48% | 49,444 | Unchanged |
| Alector Inc | $1,694,419 | 0.42% | 915,902 | +1.77% |
| Design Therapeutics Inc | $1,356,303 | 0.34% | 107,900 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 0 new positions, 5 sold out, 11 increased, 5 reduced and 14 unchanged.
Number of positions (a count, not dollars)
- New positions0
- Increased11
- Unchanged14
- Reduced5
- Sold out5
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Insmed Inc | $6,930,300 | 65,000 |
| Protagonist Therapeutics Inc | $4,658,040 | 38,000 |
| Wave Life Sciences LTD | $1,033,285 | 177,846 |
| Tyra Biosciences Inc | $638,800 | 20,000 |
| Engene Therapeutics Inc | $363,300 | 210,000 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | +782,760 | +698.89% | $26,037,516 | 894,760 |
| Legend Biotech Corp | +999,107 | +175.11% | $31,220,856 | 1,569,676 |
| Urogen Pharma LTD | +371,100 | +309.25% | $19,953,393 | 491,100 |
| Immunocore Hldgs PLC | +175,000 | +215.67% | $7,758,571 | 256,143 |
| Viridian Therapeutics Inc | +240,000 | +24.37% | $25,221,329 | 1,224,931 |
| Cullinan Therapeutics Inc | +272,792 | +39.54% | $14,778,857 | 962,792 |
| Celldex Therapeutics Inc New | +120,000 | +12.12% | $35,975,100 | 1,110,000 |
| Sutro Biopharma Inc | +196,228 | +612.50% | $3,677,349 | 228,265 |
| Travere Therapeutics Inc | +30,000 | +10.25% | $18,994,688 | 322,600 |
| Alumis Inc | +99,560 | +15.32% | $5,539,248 | 749,560 |
| Alector Inc | +15,902 | +1.77% | $1,694,419 | 915,902 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Cogent Biosciences Inc | -303,998 | -25.97% | $27,753,079 | 866,742 |
| Syndax Pharmaceuticals Inc | -250,000 | -13.48% | $30,174,000 | 1,605,000 |
| Vaxcyte Inc | -80,000 | -17.69% | $21,186,146 | 372,340 |
| Pharvaris N V | -70,000 | -13.31% | $14,456,390 | 455,750 |
| MBX Biosciences Inc | -30,000 | -32.97% | $3,575,820 | 61,000 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures